№ files_lp_4_process_3_133075
File format: docx
Character count: 10572
File size: 41 KB
Systematic review supplementary material detailing search strategies and results for economic evaluations of adjuvant therapies in stage II and III colorectal cancer.
Year:
2021
Institutes:
Walter and Eliza Hall Institute of Medical Research; Peter MacCallum Cancer Centre; University of Melbourne
Authors:
Yat Hang To, Peter Gibbs, Jeanne Tie, Maarten IJzerman, Koen Degeling
Type of document:
Systematic review supplementary material
Subjects:
Colorectal cancer, adjuvant therapy, health economics
Search period:
8th July 2021 – 10th December 2021
Databases searched:
Medline, EMBASE, Health Technology Assessment Database, National Health Service Health Economic Evaluation Database
Language:
English
Corresponding author:
Yat Hang To
ORCID ID:
0000-0002-1497-1700
Email:
[email protected]
Coverage:
Stage II and III colorectal cancer
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / city:
Australia
Topic:
Oncology / Pharmaceutical
Document Type:
Submission
Agency:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
AstraZeneca Pty Ltd
Target Audience:
Medical professionals, regulatory authorities
Validity Period:
2021-2026
Approval Date:
20 April 2021
Modification Date:
Not specified
Year:
2023
Region / city:
Australia
Topic:
Vaccination, Immunocompromised individuals, Herpes Zoster
Document type:
Government recommendation
Organization:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
PBAC
Target audience:
Healthcare professionals, Immunocompromised individuals
Period of validity:
From November 1, 2023
Approval date:
November 1, 2023
Modification date:
September 2023
Year:
2019
Region / city:
Australia
Theme:
Oncology, Chemotherapy
Document type:
Resubmission for PBS listing
Organ / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Bristol-Myers Squibb Australia Pty Ltd
Target audience:
Medical professionals, PBAC members
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2019
Region / city:
Australia
Topic:
Adjuvant melanoma treatment
Document type:
Public Summary Document
Organization / institution:
PBAC
Author:
PBAC
Target audience:
Healthcare professionals
Period of validity:
Not specified
Approval date:
July 2019
Date of changes:
July 2019
Year:
2024
Region / City:
Guangzhou, Guangdong Province, China
Topic:
Hepatocellular carcinoma, postoperative radiation therapy
Document Type:
Research article
Organization / Institution:
The Third Affiliated Hospital of Sun Yat-sen University, Qilu Hospital, Shandong University, The First Affiliated Hospital, Guangzhou Medical University
Authors:
Gao-Yuan Yang, Zhi-Wei He, Yong-Chang Tang, Feng Yuan, Ming-Bo Cao, Yu-Peng Ren, Yu-Xuan Li, Xiao-Rui Su, Zhi-Cheng Yao, Mei-Hai Deng
Target Audience:
Medical researchers, clinicians specializing in oncology and hepatobiliary surgery
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Revision:
December 9, 2023
Date of Acceptance:
January 9, 2024
Funding:
The Science and Technology Plan Project of Guangzhou, National Natural Science Foundation Cultivation Project of The Third Affiliated Hospital of Sun Yat-sen University, Natural Science Foundation of Guangdong Province, CSCO-Roche Joint Cancer Research Fund
Year:
2015
Region / City:
Southeastern/Southwest United States
Field:
Medicine, Oncology
Document Type:
Abstract
Organization:
Texas Tech University Health Sciences Center, University of Pennsylvania
Author:
Paul Trippier, Kshitij Verma, Tianzhu Zang, Trevor M. Penning
Target Audience:
Researchers, Medical Professionals
Effective Period:
Not specified
Approval Date:
Not specified
Date of Last Update:
Not specified
Year:
2012
Region / City:
Europe / Vienna
Theme:
Lung Cancer, Oncology
Document Type:
Survey
Organization / Institution:
European Society for Medical Oncology (ESMO)
Author:
Dr. Raffaele Califano
Target Audience:
Medical Oncologists, Radiation Oncologists
Period of Action:
Deadline end of February 2012
Approval Date:
N/A
Date of Changes:
N/A
Year:
2019–2024
Region:
International
Topic:
Oncology / Hepatocellular Carcinoma
Document Type:
Meta-analysis
Institution:
Multiple clinical research centers
Authors:
Various (from included RCTs)
Target Audience:
Medical researchers, oncologists, clinicians
Study Design:
Randomized controlled trials, Phase II and III
Interventions:
Nivolumab, Pembrolizumab, Atezolizumab, Sintilimab
Comparators:
Placebo, standard care, active surveillance
Outcomes Measured:
Overall survival (OS), Recurrence-free survival (RFS), adverse events (AEs)
Sample Size:
Data pooled from 10 studies
Statistical Methods:
DerSimonian-Laird random-effects model, hazard ratios (HRs), risk ratios (RRs)
Adverse Events Reported:
Fatigue, hypertension, elevated liver enzymes (grade 3+)
Publication Type:
Peer-reviewed articles
Description:
Systematic review and meta-analysis of clinical trials assessing survival outcomes and safety of adjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma after curative treatment.
Year:
2023
Region / City:
United Kingdom
Theme:
Colorectal Cancer Referral Guidelines
Document Type:
Medical Guidelines
Organization:
National Health Service (NHS)
Author:
National Institute for Health and Care Excellence (NICE), British Society of Gastroenterology (BSG), Association of Coloproctology of Great Britain and Ireland (ACPGBI)
Target Audience:
Healthcare professionals in primary and secondary care
Effective Period:
From August 2023
Date of Approval:
August 2023
Date of Amendments:
None mentioned
Year:
2017
Note:
Region / City
Topic:
Colorectal cancer screening, medical diagnostics
Document Type:
Clinical guideline
Organization / Institution:
HERC
Target Audience:
Healthcare professionals, medical reviewers
Approval Date:
November 2017
Year:
2023
Note:
Region / City
Topic:
Colorectal Cancer Screening
Document Type:
Policy
Organization:
Example Clinic
Target Audience:
Healthcare providers
References:
National Association of Community Health Centers, Colorectal Cancer Society
Year:
2021
Region / City:
New York State
Subject:
Colorectal cancer screening improvement
Document Type:
Request for Proposals
Agency / Institution:
Health Research, Inc. (HRI) and New York State Department of Health (NYSDOH)
Author:
Health Research, Inc. (HRI) and NYSDOH
Target Audience:
Federally Qualified Health Centers (FQHCs)
Period of Validity:
October 1, 2021 – December 31, 2024
Approval Date:
August 11, 2021
Amendment Date:
N/A
Year:
2019
Region / City:
Vienna, Europe
Theme:
Colorectal surgery, patient safety, surgical quality improvement
Document type:
Study protocol
Organization / Institution:
European Society of Coloproctology (ESCP)
Authors:
Mary L Venn, James Glasbey, Dmitri Nepogodiev, Elizabeth Li, Ana Minaya-Bravo, Ionut Negoi, Matteo Frasson, Richard Hooper, Charles Knowles, Dion Morton
Target audience:
Surgeons, anaesthetists, operating room staff
Study period:
Multi-phase, ongoing
Ethics approval:
Health Research Authority (HRA), REC reference 19/HRA/5656
Clinical trial registration:
NIHR CRN IRAS ID 272250, ClinicalTrials.gov NCT04270721
Funding:
ESCP and Ethicon (educational grant)
Conflict of interest:
MF consults for Johnson & Johnson Medical N.V.; other authors declare no conflicts
Type of intervention:
Hospital-level education-based quality improvement programme
Primary outcome:
30-day anastomotic leak rate
Year:
2019
Region / City:
Wellington, New Zealand
Topic:
Colorectal cancer, chemotherapy regimens
Document type:
Draft definitions
Organization / Institution:
Ministry of Health, New Zealand
Author:
Ministry of Health
Target audience:
Medical oncologists, pharmacists, nurse specialists, other DHB staff
Period of validity:
Not specified
Approval date:
Not specified
Date of last modification:
Not specified
Year:
2026
Region / City:
Not specified
Topic:
Colorectal cancer, miRNA, HOXB7, GALNT5, Cancer cell migration
Document type:
Research Supplementary Materials
Organization/Institution:
Not specified
Author:
Not specified
Target audience:
Researchers, medical professionals
Effective period:
Not specified
Approval date:
Not specified
Date of modification:
Not specified
Contextual description:
Supplementary materials detailing experimental methods and procedures used to study the role of miR-196b-5p in cancer cell migration and its potential as a prognostic factor in colorectal cancer.
Year:
2023
Region / city:
Global
Subject:
Postoperative biomarkers, colorectal cancer
Document Type:
Research data
Institution:
Various research institutions
Author:
Multiple authors
Target Audience:
Researchers, medical professionals
Effective Period:
N/A
Approval Date:
24.02.2023
Revision Date:
N/A
Note:
Contextual description
Year:
2010-2017
Region / City:
Africa, Latin America
Topic:
Colorectal Cancer, Cancer Registries
Document Type:
Statistical Table
Institution:
Various Cancer Registries
Authors:
Not specified
Target Audience:
Researchers, Medical Professionals
Period of Validity:
2010-2017
Date of Approval:
Not provided
Date of Revisions:
Not provided
Year:
Not specified
Region / city:
Not specified
Topic:
Colorectal cancer, gene expression, proteomics
Document type:
Research data
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers in oncology and molecular biology
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2017
Region / City:
Not specified
Topic:
Colorectal Surgery, ERAS Protocol
Document Type:
Medical Protocol
Organization / Institution:
STTAR Clinic
Author:
Troy Beaumont
Target Audience:
Healthcare professionals involved in colorectal surgery
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
10/18/17
Year:
2026
Region / City:
Europe, United States, Australia, Canada
Subject:
Colorectal Cancer Research
Document Type:
Funding and Acknowledgements Summary
Institutions:
National Cancer Institute, National Institutes of Health, University Hospital Center of Nantes, German Research Council, Instituto de Salud Carlos III, Charles University, and multiple international cancer research consortia
Authors:
Various contributing researchers from multiple studies
Target Audience:
Scientific community and research collaborators
Funding Sources:
NIH, NCI, European Union, regional councils, cancer societies, foundations, public–private partnerships
Research Programs:
GECCO, ASTERISK, ATBC, BWHS, CLUE II, ColoCare, CCFR, COLON, Nqplus, COLO2&3, CORECT, CORSA, CPS-II, CRCGEN, Czech Republic CCS, DACHS, DALS, EDRN, EPIC
Acknowledged Services:
Genotyping/Sequencing by CIDR, Scientific Computing Infrastructure at Fred Hutch
Collaborating Registries:
Maryland Cancer Registry, state and international cancer registries
Description:
Compilation of funding acknowledgements, institutional collaborations, and registry contributions across multiple international colorectal cancer studies, providing transparency on grants, support, and research infrastructure involved in data collection and analysis.